Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term cohort study of switching to enoverin-containing ART in HIV-1-positive patients with dyslipidemia or weight gain
ChiCTR2500099875Phase 4Recruiting
- Sponsor
- Chest Hospital of Guangxi Zhuang Autonomous Region
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ainuovirine in human immunodeficiency virus infection (HIV), sponsored by Chest Hospital of Guangxi Zhuang Autonomous Region. Primary endpoints: HIV RNA viral load at 96 weeks and CD4 T cell count at 96 weeks. Started Mar 2025; status: recruiting.
02
Drugs
ainuovirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2500099875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099875.